Affiliation:
1. Department of Interventional Radiology, The Fourth Medical Centre, Chinese PLA (People's Liberation Army), Beijing 100089, China
2. Department of Interventional Radiology, The Third Affiliated Hospital of Harbin Medical University, Harbin 150000, China
3. Department of Radiology, No. 2 People's Hospital of Changzhou, Nanjing Medical University, Changzhou 213003, China
Abstract
Background:
Camrelizumab, which was launched in China on May 29, 2019, is a humanized
anti-programmed cell death-1 (PD-1) antibody. It is used for the treatment of complicated
or refractory classic Hodgkin's lymphoma with at least second-line chemotherapy. On March 4,
2020, camrelizumab was approved as a second-line drug in China for the treatment of advanced hepatocellular
carcinoma. Currently, camrelizumab is undergoing clinical research for advanced solid
tumors such as liver cancer, gastric cancer, esophageal cancer, and lung cancer, and all have shown
clinical efficacy.
Objective:
This review describes preclinical studies on camrelizumab and its efficacy and safety in
clinical studies in various tumors.
Methods:
A literature search was conducted on basic research and clinical trials of camrelizumab
determined its pharmacology, toxicology, pharmacokinetic properties, and current clinical research
status. We also analyzed the difference between camrelizumab and other PD-1 antibodies.
Results:
The results of preclinical studies show that camrelizumab binds to the PD-1 receptor and
has stable anti-tumor activity in a dose-dependent manner. Clinical studies show that camrelizumab
has therapeutic effects on a variety of tumors. The incidence of adverse reactions with camrelizumab
is low, with most being mild, reversible, and predictable.
Conclusion:
This review summarizes the current status of preclinical and clinical studies on camrelizumab.
Current research confirms that camrelizumab alone or in combination with other drugs
shows significant anti-cancer activity and a low incidence of adverse reactions. However, further
studies are needed to verify the application potential of camrelizumab in a variety of tumors.
Funder
National Natural Scientific Foundation of China
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmacology (medical),Cancer Research,Drug Discovery,Oncology,General Medicine
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献